Found: 8
Select item for more details and to access through your institution.
Artesunate shows potent anti-tumor activity in B-cell lymphoma.
- Published in:
- Journal of Hematology & Oncology, 2018, v. 11, p. 1, doi. 10.1186/s13045-018-0561-0
- By:
- Publication type:
- Article
The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.
- Published in:
- British Journal of Haematology, 2016, v. 175, n. 1, p. 102, doi. 10.1111/bjh.14201
- By:
- Publication type:
- Article
Mass Cytometry of Follicular Lymphoma Tumors Reveals Intrinsic Heterogeneity in Proteins Including HLA-DR and a Deficit in Nonmalignant Plasmablast and Germinal Center B-Cell Populations.
- Published in:
- Cytometry. Part B, 2017, v. 92, n. 1, p. 79, doi. 10.1002/cyto.b.21498
- By:
- Publication type:
- Article
Expression of S100A4 by a variety of cell types present in the tumor microenvironment of human breast cancer.
- Published in:
- International Journal of Cancer, 2007, v. 121, n. 7, p. 1433, doi. 10.1002/ijc.22850
- By:
- Publication type:
- Article
Activation of the CAMP signaling pathway increases apoptosis in human B-precursor cells and is associated with downregulation of Mcl-1 expression.
- Published in:
- Journal of Cellular Physiology, 1999, v. 180, n. 1, p. 71, doi. 10.1002/(SICI)1097-4652(199907)180:1<71::AID-JCP8>3.0.CO;2-N
- By:
- Publication type:
- Article
Myeloid cell leukaemia 1 has a vital role in retinoic acid-mediated protection of Toll-like receptor 9-stimulated B cells from spontaneous and DNA damage-induced apoptosis.
- Published in:
- Immunology, 2016, v. 149, n. 1, p. 62, doi. 10.1111/imm.12629
- By:
- Publication type:
- Article
PI3K/Akt-dependent Epo-induced signalling and target genes in human early erythroid progenitor cells.
- Published in:
- British Journal of Haematology, 2006, v. 135, n. 1, p. 117, doi. 10.1111/j.1365-2141.2006.06252.x
- By:
- Publication type:
- Article
The DLBCL90 gene‐expression assay identifies double‐hit lymphomas with high sensitivity in patients from two phase II clinical trials with high‐risk diffuse large B‐cell lymphoma.
- Published in:
- EJHaem, 2021, v. 2, n. 1, p. 107, doi. 10.1002/jha2.109
- By:
- Publication type:
- Article